Disc Medicine, Inc.

Equities

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
31.01 ^USD	+2.14%		+2.78%	-46.31%

09/05	Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/04	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

December 21, 2023 at 03:00 am IST

Disc Medicine, Inc. announced that, after a distinguished 28-year career, including over 6 years at Disc, Brian MacDonald, MB, ChB, PhD, will be retiring from his role as Chief Innovation Officer. Dr. MacDonald plans to stay involved with Disc, transitioning from his current role to become Chair of Disc?s Scientific Advisory Board.

Latest news about Disc Medicine, Inc.

Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	08/04	MT
Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	02/04	MT
Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating	02/04	MT
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating	02/04	MT
Stifel Adjusts Price Target on Disc Medicine to $71 From $104, Keeps Buy Rating	02/04	MT
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept	02/04	MT
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Top Midday Decliners	01/04	MT
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	01/04	MT
Raymond James Downgrades Disc Medicine to Outperform From Strong Buy, Cuts Price Target to $40 From $75	01/04	MT
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	01/04	CI
Wedbush Raises Disc Medicine Price Target to $84 From $79, Maintains Outperform Rating	21/03	MT
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Stifel Adjusts Price Target on Disc Medicine to $104 From $76, Maintains Buy Rating	12/03	MT
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer	26/02	MT
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer	26/02	CI
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	20/02	MT
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	20/02	CI
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation	09/02	MT
Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment	09/02	DJ
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	09/02	CI
Disc Medicine, Inc. Announces Promotion of Jonathan Yu to Chief Operating Officer	07/02	CI
Disc Medicine, Inc. Announces CFO Changes	07/02	CI
Disc Medicine Insider Sold Shares Worth $6,934,125, According to a Recent SEC Filing	26/01	MT

Chart Disc Medicine, Inc.

Duration

Period

More charts

Company Profile

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.36 USD

Average target price

57.33 USD

Spread / Average Target

+88.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DISC MEDICINE, INC.	-46.31%	751M
MODERNA, INC.	+26.37%	44.96B
IQVIA HOLDINGS INC.	-1.01%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B
BIO-TECHNE CORPORATION	+6.23%	12.75B
MEDPACE HOLDINGS, INC.	+26.99%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B

Other Biotechnology & Medical Research